Psychiatry and Neurology, Neurology · Kirkland, WA
NPI
1861474793
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
12039 NE 128th St, Suite 300
Kirkland, WA, 98034
Phone (425) 899-3123
Groups this clinician bills Medicare through
Medicare paid, 2024
$52K
979 services
Medicare patients, 2024
189
Average age 77
Drug cost, 2024
$1.2M
3,588 prescriptions
Company payments, 2025
$535
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alida F Griffith was code 99214 (office e&m - established), 396 times for 162 patients. In total Alida F Griffith billed 979 services in 16 codes, and Medicare paid $52K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 396 | 162 | $72.68 | $29K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 368 | 155 | $13.23 | $4,870 |
| 64616 Musculoskeletal | Facility | 50 | 14 | $112.67 | $5,633 |
| 95874 Musculoskeletal | Facility | 44 | 14 | $14.89 | $655 |
| 99205 Office E&M - New | Facility | 37 | 37 | $133.69 | $4,946 |
| 99215 Office E&M - Established | Facility | 36 | 31 | $115.09 | $4,143 |
By year: 2022 $37K for 494 services; 2023 $47K for 600 services; 2024 $52K for 979 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alida F Griffith prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 652 prescriptions and refills. In total Alida F Griffith wrote 3,588 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 652 | 1,424 | 206 | $25K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 547 | 1,265 | 160 | $49K |
| Rytary Carbidopa/Levodopa | 231 | 334 | 46 | $310K |
| Donepezil Hcl Generic | 147 | 331 | 50 | $2,925 |
| Gabapentin Generic | 138 | 329 | 47 | $2,111 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 133 | 278 | 35 | $2,487 |
| Rasagiline Mesylate Generic | 120 | 324 | 42 | $17K |
| Entacapone Generic | 120 | 233 | 38 | $19K |
| Amantadine Amantadine Hcl | 107 | 250 | 36 | $6,803 |
| Escitalopram Oxalate Generic | 104 | 202 | 26 | $1,426 |
| Quetiapine Fumarate Generic | 74 | 140 | 20 | $1,280 |
| Nuplazid Pimavanserin Tartrate | 70 | 86 | 14 | $422K |
| Memantine Hcl Generic | 60 | 135 | 18 | $1,619 |
| Clonazepam Generic | 58 | 84 | 16 | $441 |
| Mirtazapine Generic | 55 | 113 | 18 | $1,138 |
Brand drugs: 507 claims; generic drugs: 3,081 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alida F Griffith $535 ($535 in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $120.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 4 | $120 |
| Merz Pharmaceuticals, LLC | 3 | $81.45 |
| Abbvie Inc. ABBV | 2 | $56.66 |
| Boston Scientific Corporation BSX | 2 | $44.95 |
| Abbott Laboratories ABT | 1 | $43.16 |
| CSL Behring CSL.AX | 2 | $42.95 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $29.71 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $25.06 |
| TG Therapeutics, Inc. TGTX | 1 | $22.38 |
| Argenx US, Inc. ARGX | 1 | $19.27 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.